Toggle navigation
Home
Search
Services
Blog
Contact
About
Development of an Antidote for E coli 0157 - H7 Verotoxin
Kink, John
Ophidian Pharmaceuticals, Inc., Madison, WI, United States
Search 3 grants from John Kink
Search grants from Ophidian Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
University of Virginia
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Center for Systems Neurogenetics of Addiction
Serine/threonine Protein Phosphatase 1 in Insulin resistance and Type 2 Diabetes
Mechanisms of Reciprocal Inhibition Development
Racial and Ethnic Approaches to Community Health US
New Rfgd Treatments for Small Diameter Vascular Grafts
Recently added grants:
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages
Administrative Core: U19
Using siglecs and their ligands to treat allergic diseases SALTAD
Data Management and Bioinformatics Core
Mechanisms of vaccine protection against AIDS-associated Cryptococcus infection
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44DK048210-02
Application #
2148352
Study Section
Special Emphasis Panel (ZRG5-MBC-2 (01))
Project Start
1994-06-01
Project End
1998-03-31
Budget Start
1996-04-01
Budget End
1997-03-31
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Ophidian Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Madison
State
WI
Country
United States
Zip Code
53711
Related projects
NIH 1997
R44 DK
Development of an Antidote for E coli 0157 - H7 Verotoxin
Kink, John / Ophidian Pharmaceuticals, Inc.
NIH 1996
R44 DK
Development of an Antidote for E coli 0157 - H7 Verotoxin
Kink, John / Ophidian Pharmaceuticals, Inc.
Comments
Be the first to comment on this grant